Abstract
This paper reviews regulatory frameworks for cell therapy products in Japan. Two procedures are used to investigate the use of new cell therapy products in Japan. One is to perform clinical trials in accordance with the provisions of the Pharmaceuticals Affairs Act (PAA); the other is to perform clinical research in accordance with the provisions of the Medical Practitioners Act. For full commercialization of medical products in Japan, we must consider the universal health care system. All medical products used to treat patients in the system must be approved, in accordance with the provisions of the PAA, as drugs or medical devices. Thus, researchers in academia who have developed new cell therapy products should consider performing clinical trials in accordance with the provisions of the PAA to test their products clinically. This article describes development and review processes for new drug/device applications in accordance with the provisions of the PAA and gives an example of clinical review of a cell therapy product by the Pharmaceuticals and Medical Devices Agency.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shikano M. PMDA’s perspective on quality and non-clinical evaluation of cell/tissue-based products. In: PMDA 5th international symposium on biologics, August 26, 2010, Tokyo. http://www.pmda.go.jp/english/past/2010bio_sympo.html. Accessed 22 February 2012.
Ethical guidance for clinical research, Ministerial Notification No. 459 of MHLW (31 June 2008).
Guidance for clinical research using human stem cells, Ministerial Notification No. 380 of MHLW (1 November 2010).
Guidance for gene therapy clinical research, Ministerial Notification No. 1 of Ministry of Education, Science, Sports and Culture and MHLW (1 December 2008).
General Principles for the handling and use of cell/tissue-based products, MHLW Notification No. 1314 (26 December 2000).
About the advanced therapy evaluation system, MHLW (in Japanese). http://www.mhlw.go.jp/topics/2008/04/tp0402-1.html. Accessed 22 February.
Guidelines on ensuring quality and safety of autologous human cell/tissue-based products, MHLW Notification No. 0208004 (8 February 2008).
Guidelines on ensuring quality and safety of allogeneic human cell/tissue-based products, MHLW Notification No. 0912007 (12 September 2008).
Review report of JACE. http://www.pmda.go.jp/english/service/medical_devices.html. Accessed 22 February 2012.
Profile of services 2011–2012, PMDA, p. 12. http://www.pmda.go.jp/english/about/pdf/profile_of_services.pdf. Accessed 22 February 2012.
Summary of review related operations of PMDA (in Japanese; partly changed). http://www.pmda.go.jp/operations/shonin/outline.html. Accessed 22 February 2012.
Yanagi K. PMDA’s perspective on the clinical evaluation of cell/tissue-based products. In: PMDA 4th international symposium on biologics, 9 October 2009, Tokyo. http://www.pmda.go.jp/english/past/2009bio_sympo_2.html. Accessed 22 February 2012.
Acknowledgments
The authors are grateful to Professor Brian Purdue, Medical English Communications Center of the University of Tsukuba, for reviewing this manuscript. Kennichi Yanagi has served in the Office of Biologics II, the Pharmaceuticals and Medical Devices Agency, as a clinical reviewer.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yanagi, K., Fukuda, E., Jotatsu, Y. et al. Regulatory frameworks for cell therapy products in Japan. J Artif Organs 15, 325–330 (2012). https://doi.org/10.1007/s10047-012-0653-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-012-0653-5